Spoke with Ladenburg Thalmann Analyst Matthew Kaplan
I was surprised that the Star Analyst listed for Aradigm was such a high ranking analyst with a major firm. I had to do some research to find him and you may want to do the same. Kaplan is a managing director and Ladenburg Thalmann is apparently one of the oldest investment firms on Wall Street.
I asked him if following Phase 2b approval of liposomal ciprofloxacin whether the FDA would allow the drug to be marketed/sold in limited quantities in Phase III. He said it is highly unlikely. However, he feels the company should have enough cash to get through Phase III trials. This was good news to me because I am still generally worried about the companies cash position.
I'm no pro and I some time mix up my numbers but I think this company has 35 million cash and can easily get through phase III. Remember the phases only take 4 weeks. Thats a short time. Getting 100 people for the phase IIb they are in I hope goes quickly. I own 20,000 shares and will wait the year or so. Thanks for the post.